Tumor hypoxia enhances non-small cell lung cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9664-9677

  Zhang, Jun ^a   Cao, Ji ^a   Ma, Shenglin ^b,c   Dong, Rong ^a   Meng, Wen ^b   Ying, Meidan ^a   Weng, Qinjie ^a   Chen, Zibo ^e   Ma, Jian ^a   Fang, Qingxia ^d   He, Qiaojun ^a   Yang, Bo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^d ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY   (China)

Author keywords

Hypoxia; Macrophage; Metastasis; NSCLC; Polarization

Indexed keywords

ALPHA INTERFERON A; CD209 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER PATIENT; CELL INFILTRATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MACROPHAGE; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PHENOTYPE; POLARIZATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CELL HYPOXIA; CELL LINE; CELL POLARITY; CELL PROLIFERATION; DISEASE COURSE; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; PIG; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; XENOGRAFT;

ANIMALS; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE; CELL LINE, TUMOR; CELL POLARITY; CELL PROLIFERATION; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HETEROGRAFTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; SWINE;

EID: 84928919804     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1856     Document Type: Article

References (53)

1. Martinez FO, Sica A, Mantovani A and Locati M. Macrophage activation and polarization. Front Biosci. 2008; 13:453-461.
2. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003; 3(1):23-35.
3. Gordon S and Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005; 5(12):953-964.
4. Murdoch C, Muthana M, Coffelt SB and Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008; 8(8):618-631.
5. Mantovani A, Allavena P, Sica A and Balkwill F. Cancerrelated inflammation. Nature. 2008; 454(7203):436-444.
6. Comito G, Giannoni E, Segura CP, Barcellos-de-Souza P, Raspollini MR, Baroni G, Lanciotti M, Serni S and Chiarugi P. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene. 2013.
7. Cordes C, Bartling B, Simm A, Afar D, Lautenschlager C, Hansen G, Silber RE, Burdach S and Hofmann HS. Simultaneous expression of Cathepsins B and K in pulmonary adenocarcinomas and squamous cell carcinomas predicts poor recurrence-free and overall survival. Lung Cancer. 2009; 64(1):79-85.
8. Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J, Augustin N, Nielsen BS, Almholt K, Bogyo M, Peters C and Reinheckel T. Tumor cellderived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006; 66(10):5242-5250.
9. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T and Joyce JA. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010; 24(3):241-255.
10. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ and Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005; 23(35):8959-8967.
11. Lewis C and Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol. 2005; 167(3):627-635.
12. Rahat MA, Bitterman H and Lahat N. Molecular mechanisms regulating macrophage response to hypoxia. Front Immunol. 2011; 2:45.
13. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK and Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol. 2005; 175(1):342-349.
14. Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR and Malkinson AM. Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol. 2010; 176(6):2972-2985.
15. Weigert A and Brune B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide. 2008; 19(2):95-102.
16. Murdoch C, Giannoudis A and Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 2004; 104(8):2224-2234.
17. Murdoch C and Lewis CE. Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer. 2005; 117(5):701-708.
18. Lewis CE and Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66(2):605-612.
19. Chen P and Bonaldo P. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. Int Rev Cell Mol Biol. 2013; 301:1-35.
20. Bingle L, Brown NJ and Lewis CE. The role of tumourassociated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002; 196(3):254-265.
21. Vaupel P and Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-239.
22. Pettersen JS, Fuentes-Duculan J, Suarez-Farinas M, Pierson KC, Pitts-Kiefer A, Fan L, Belkin DA, Wang CQ, Bhuvanendran S, Johnson-Huang LM, Bluth MJ, Krueger JG, Lowes MA and Carucci JA. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol. 131(6):1322-1330.
23. Dominguez-Soto A, Sierra-Filardi E, Puig-Kroger A, Perez-Maceda B, Gomez-Aguado F, Corcuera MT, Sanchez-Mateos P and Corbi AL. Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10. J Immunol. 186(4):2192-2200.
24. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL and O'Byrne KJ. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-smallcell lung cancer. J Clin Oncol. 2003; 21(3):473-482.
25. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC, Jr. and Raleigh JA. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998; 71(2):270-277.
26. Liu W, Guo M, Xu YB, Li D, Zhou ZN, Wu YL, Chen Z, Kogan SC and Chen GQ. Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood. 2006; 107(2):698-707.
27. Gerke P, Bording C, Zeis B and Paul RJ. Adaptive haemoglobin gene control in Daphnia pulex at different oxygen and temperature conditions. Comp Biochem Physiol A Mol Integr Physiol. 2011; 159(1):56-65.
28. Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC, Chen CJ, Hsiung CA and Su WC. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer. 132(9):1977-1985.
29. Mantovani A, Sozzani S, Locati M, Allavena P and Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23(11):549-555.
30. Sica A, Schioppa T, Mantovani A and Allavena P. Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006; 42(6):717-727.
31. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi M, Musiani P, Zanovello P and Bronte V. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A. 2005; 102(11):4185-4190.
32. Serafini P, Borrello I and Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006; 16(1):53-65.
33. Cho HJ, Jung JI, Lim do Y, Kwon GT, Her S and Park JH. Bone marrow-derived, alternatively activated macrophages enhance solid tumor growth and lung metastasis of mammary carcinoma cells in a Balb/C mouse orthotopic model. Breast Cancer Res. 2012; 14(3):R81.
34. Johnson GL and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002; 298(5600):1911-1912.
35. Colombo MP and Mantovani A. Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res. 2005; 65(20):9113-9116.
36. Francia G, Cruz-Munoz W, Man S, Xu P and Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 2011; 11(2):135-141.
37. Werno C, Menrad H, Weigert A, Dehne N, Goerdt S, Schledzewski K, Kzhyshkowska J and Brune B. Knockout of HIF-1alpha in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis. 2010; 31(10):1863-1872.
38. Acosta-Iborra B, Elorza A, Olazabal IM, Martin-Cofreces NB, Martin-Puig S, Miro M, Calzada MJ, Aragones J, Sanchez-Madrid F and Landazuri MO. Macrophage oxygen sensing modulates antigen presentation and phagocytic functions involving IFN-gamma production through the HIF-1 alpha transcription factor. J Immunol. 2009; 182(5):3155-3164.
39. Takeda N, O'Dea EL, Doedens A, Kim JW, Weidemann A, Stockmann C, Asagiri M, Simon MC, Hoffmann A and Johnson RS. Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev. 2010; 24(5):491-501.
40. Escribese MM, Casas M and Corbi AL. Influence of low oxygen tensions on macrophage polarization. Immunobiology. 2012; 217(12):1233-1240.
41. Lee K, Zhang H, Qian DZ, Rey S, Liu JO and Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A. 2009; 106(42):17910-17915.
42. Luo YP, Zhou H, Krueger J, Kaplan C, Liao D, Markowitz D, Liu C, Chen T, Chuang TH, Xiang R and Reisfeld RA. The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene. 2010; 29(5):662-673.
43. Sica A and Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007; 117(5):1155-1166.
44. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 374(Pt 1):1-20.
45. Friday BB and Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res. 2008; 14(2):342-346.
46. Naugler WE and Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008; 14(3):109-119.
47. Naka T, Nishimoto N and Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002; 4 Suppl 3:S233-242.
48. Wang Q, Ni H, Lan L, Wei X, Xiang R and Wang Y. Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Res. 2010; 20(6):701-712.
49. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N, Descamps P, Gamelin E, Gascan H, Hebbar M and Jeannin P. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007; 110(13):4319-4330.
50. Lewis JS, Lee JA, Underwood JC, Harris AL and Lewis CE. Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol. 1999; 66(6):889-900.
51. Anzinger JJ, Chang J, Xu Q, Barthwal MK, Bohnacker T, Wymann MP and Kruth HS. Murine bone marrow-derived macrophages differentiated with GM-CSF become foam cells by PI3Kgamma-dependent fluid-phase pinocytosis of native LDL. J Lipid Res. 2012; 53(1):34-42.
52. Solinas G, Schiarea S, Liguori M, Fabbri M, Pesce S, Zammataro L, Pasqualini F, Nebuloni M, Chiabrando C, Mantovani A and Allavena P. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol. 2010; 185(1):642-652.
53. Zhang B, Wang J, Gao J, Guo Y, Chen X, Wang B, Rao Z and Chen Z. Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma. J Cell Biochem. 2009; 107(1):134-143.